度伐利尤单抗(Durvalumab) - 药物靶点：PDL1_在研适应症：局限期小细胞肺癌，子宫癌，晚期子宫内膜癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Durvalumab (Genetical Recombination)、Durvalumab (genetical recombination) (JAN)、Durvalumab (USAN/INN)

+ [10]

靶点

PDL1

作用机制

PDL1抑制剂(程序性死亡配体1抑制剂)

治疗领域

肿瘤消化系统疾病呼吸系统疾病+ [12]

在研适应症

局限期小细胞肺癌子宫癌晚期子宫内膜癌+ [181]

非在研适应症

急性髓性白血病大肠腺癌晚期头颈癌+ [62]

原研机构

在研机构

+ [17]

非在研机构

Mirati Therapeutics, Inc.

MedPacto, Inc.

Juno Therapeutics, Inc.

+ [4]

最高研发阶段批准上市

首次获批日期

美国 (2017-05-01),

尿路上皮癌

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)

登录后查看时间轴

结构/序列

Sequence Code 10069506H

来源: *****

Sequence Code 13384675L

来源: *****

关联

863

项与度伐利尤单抗相关的临床试验

NCT06287775

/ Recruiting临床1/2期IIT

A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer

This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.

开始日期2025-08-17

申办/合作机构

National Cancer Institute

NCT06608940

/ Not yet recruiting临床1/2期IIT

A Phase Ib/II Study of BC3402, a Novel Anti-TIM3 Agent, in Combination With Tremelimumab Plus Durvalumab (STRIDE) in Advanced, Unresectable Hepatocellular Carcinoma

The purpose of this study is to test the safety and efficacy of an investigational (experimental) product called BC3402. This product is considered experimental because it is not approved by the U.S. Food and Drug Administration (FDA).

开始日期2025-06-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT06274879

/ Not yet recruiting临床2期

Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer Undergoing Standard of Care Chemo-immune Checkpoint Inhibitor -Therapy: a Phase II, Multicenter, Randomized and Controlled

The goal of this clinical trial is to provide evidence for the general tolerability of radiofrequency ablation (bRFA) in patients with unresectable bile duct cancer undergoing systemic palliative treatment consisting of chemotherapy (gemcitabine and cisplatin) plus durvalumab (immune-checkpoint-inhibitor, ICI). The main question it aims to answer is whether it is safe to combine chemotherapy (gemcitabine and cisplatin) and immunotherapy (durvalumab) - CICI therapy.
Participants will be assigned to either the control group or the experimental group. In the control group, the standard of care consists of endoscopy with stent placement in the bile duct and CICI, whereas in the experimental group, bRFA will be performed in addition to the standard of care. Participants will be followed up for 6 months, during the follow-up, the stage of the tumor, blood examination, the duration of the stent from the insertion until its failure, adverse events and quality of life will be examined.
Researchers will compare the standard of care alone to the experimental group to see if the additional bRFA procedure causes higher or no difference in adverse events rate.

开始日期2025-06-01

申办/合作机构

Insel Gruppe AG

[+1]

100 项与度伐利尤单抗相关的临床结果

登录后查看更多信息

100 项与度伐利尤单抗相关的转化医学

登录后查看更多信息

100 项与度伐利尤单抗相关的专利（医药）

登录后查看更多信息

1,947

项与度伐利尤单抗相关的文献（医药）

2025-12-31·Human Vaccines & Immunotherapeutics

From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment

Review

作者: Fang, Ye-Ying ; Chen, Gang ; Huang, Fang-Ju ; He, Rong-Quan ; Su, Qin-Yan ; Wen, Jia-Ying ; Li, Jian-Jun ; Qin, Di-Yuan ; Chi, Bang-Teng ; Chen, Yi-Yang ; Zeng, Jian-Jia ; Wang, Lei ; Yang, Li-Hua ; Lin, Qian

Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC, Wan fang Data, CNKI and VIP databases, spanning contributions from 32 countries, 589 institutions and 3,200 authors. The analysis identified "PD-L1," "PD-1" and "pembrolizumab" as central research foci, while "immune checkpoint inhibitors," "tumor immune microenvironment," "tertiary lymphoid structures" and "durvalumab" emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymphoid structures within the tumor microenvironment as a promising target for future research. This study offers a strategic overview of the evolving landscape of CCA immunotherapy, providing valuable insights to guide future scientific endeavors in this domain.

2025-12-01·Journal of Gastrointestinal Cancer

The Efficacy and Safety of Durvalumab and Tremelimumab with Concomitant Treatment for MSS/pMMR Metastatic Colorectal Cancer: A Single Arm Meta-Analysis

Article

作者: Zhang, Danning ; Chen, Tianyu

OBJECTIVES:

To address the issue that most microsatellite-stable (MSS) and proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) patients have minimal response to immunotherapy, this meta-analysis evaluated the efficacy and safety of durvalumab and tremelimumab with concomitant treatment in treating MSS/pMMR metastatic colorectal cancer.

METHODS:

All included trials were prospective studies with a median patient age of 63 years, of which 94.2% were MSS/pMMR mCRC patients, with a male to female ratio of 1.5:1. Based on durvalumab and tremelimumab treatment, one study performed surgical resection on resectable cases, while the other four studies performed radiotherapy or chemotherapy on unresectable cases. Analyses include objective response rate (ORR).etc. for drug activity, overall survival (OS) and progression-free survival (PFS) for therapeutic efficacy, and adverse events (AEs) for safety. The risk of bias was assessed by sensitivity analysis.

RESULTS:

5 studies involving 228 patients were included in this meta-analysis. The pooled estimates showed a median OS of 9.26 months, median PFS of 2.53 months, partial response (PR) of 13.6%, stable disease (SD) of 32.8%, ORR of 12.5% and disease control rate (DCR) of 65.4%. AEs were generally low, with pruritus (27.5%), diarrhea (28.8%), and fatigue (53.9%) being the most common, while other AEs occurred at less frequencies.

CONCLUSIONS:

Durvalumab and tremelimumab with concomitant treatment for MSS/pMMR mCRC patients is relatively effective and safe, which is helpful in addressing the problem of mCRC with MSS/pMMR that has minimal response to immunotherapy.

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer

Article

作者: Chen, Cecil ; Zhou, Diansong ; Fan, Chunling ; Ren, Song ; Phipps, Alex ; Zotkiewicz, Magdalena ; Wang, Julie ; Lim, KyoungSoo ; Kim, Chong ; Xynos, Ioannis ; Abegesah, Aburough ; Oh, Do-Youn ; Gibbs, Megan

PURPOSE:

Durvalumab in combination with gemcitabine/cisplatin has shown a favorable benefit-risk profile in the TOPAZ-1 study for advanced biliary tract cancers (BTC). This analysis evaluated the population pharmacokinetics (PopPK) of durvalumab, and exposure-response for efficacy and safety (ERES) of TOPAZ-1.

METHODS:

The PopPK model for durvalumab was updated using data from 5 previously analysed studies and TOPAZ-1. Individual exposure metrics were derived from the individual empirical Bayes estimates as drivers for exposure-response (ER) analysis related to efficacy and safety.

RESULTS:

Consistent with previous analyses, the durvalumab pharmacokinetics in BTC followed a 2-compartment model with time-dependent clearance. The final population parameters were: CL, 0.298 L/day; V1, 3.42 L; V2, 1.99 L; Q, 0.452 L/day; and the time dependent clearance suggests that the clearance could decrease up to 39% over the time course of treatment. There were 111 patients (3.53%) with treatment-emergent ADA positive in the pooled group of 6 studies, and the exposure was comparable for ADA positive and negative patients. Covariates had minimal clinical impact on PopPK parameters. No significant associations were found between exposure and overall survival (OS), progression-free survival (PFS), using Cox proportional analysis (CPH). Logistic regression analysis indicated no significant relationship between the exposure and relevant adverse events measures of Grade 3 and higher treatment-related AE, Grade 3 and higher treatment-related AESI (AEs of special interest), or AE leading to treatment discontinuation.

CONCLUSIONS:

No dose adjustment for durvalumab is needed based on PopPK and ERES analyses. The analysis supports the TOPAZ-1 regimen for patients with advanced BTC.

1,957

项与度伐利尤单抗相关的新闻（医药）

2025-02-21

·Insight数据库

第 7 项！阿斯利康「度伐利尤单抗」新适应症国内报上市

2 月 21 日，CDE 官网显示，阿斯利康度伐利尤单抗注射液新适应症上市申请获受理。根据生物制品注册分类标准，3.1类是境外生产的境外已上市、境内未上市的生物制品申报上市。 Insight 数据库显示，这是度伐利尤单抗在国内申报上市的第 7 项适应症。来源：CDE 官网度伐利尤单抗是一种人源化的 PD-L1 单克隆抗体，能够阻断 PD-L1 与 PD-1 和 CD80 的结合，从而阻断肿瘤免疫逃逸策略并恢复被抑制的免疫反应。目前，该产品已在美国获批 8 项适应症，包括：接受铂类药物为基础的化疗同步放疗后未出现疾病进展的不可切除、III期非小细胞肺癌（NSCLC）；联合依托泊苷和卡铂或顺铂，一线治疗广泛期小细胞肺癌（ES-SCLC）；联合吉西他滨和顺铂，一线治疗局部晚期或转移性胆道癌（BTC）；联合替西木单抗，一线治疗不可切除的肝细胞癌 (HCC) 成人患者；联合替西木单抗和含铂化疗，一线治疗无致敏 EGFR 突变或 ALK 基因突变的转移性 NSCLC 成人患者；联合卡铂和紫杉醇，一线治疗 dMMR 原发性晚期或复发性子宫内膜癌；用于可切除 NSCLC 的新辅助/辅助治疗；接受铂类化疗和放射治疗后病情未进展的局限期小细胞肺癌 (LS-SCLC) 。在中国市场，度伐利尤单抗也已获批 3 项适应症，分别为：接受铂类化疗和放疗后未出现疾病进展的不可切除、III期 NSCLC ；联合依托泊苷和卡铂或顺铂，一线治疗 ES-SCLC；联合吉西他滨和顺铂一线治疗局部晚期或转移性 BTC。阿斯利康在 2024 年财报中披露，未来 2 年，度伐利尤单抗将在中国斩获 3 项新适应症监管批准，包括 NSCLC 新辅助/辅助治疗、LS-SCLC 和联合替西木单抗一线治疗 NSCLC。来源：阿斯利康财报综合阿斯利康过往新闻稿，NSCLC 新辅助/辅助治疗、联合替西木单抗一线治疗 NSCLC 适应症均已在国内报上市，推测本次申报适应症为 LS-SCLC。自上市以来，度伐利尤单抗销售额一路高歌猛进。2024 年全球销售额达 47.17 亿美元，是阿斯利康产品管线中收入前三的当家产品。来源：Insight 数据库封面来源：企业logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：月牙 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn 多样化功能、可溯源数据…… Insight 数据库网页版等你体验点击阅读原文，立刻解锁！

临床3期财报上市批准

2025-02-21

·医药观澜

阿斯利康抗PD-L1单抗癌症新药新适应症在华申报上市

▎药明康德内容团队报道今日（2月21日），中国国家药监局药品审评中心（CDE）官网最新公示，阿斯利康（AstraZeneca）的抗PD-L1单抗度伐利尤单抗注射液又一项新适应症上市申请获得受理，具体适应症尚未披露。公开资料显示，度伐利尤单抗此前已经在中国获批治疗非小细胞肺癌、广泛期小细胞肺癌、胆道癌适应症，此外该产品还有至少3项新适应症上市申请已经获CDE受理，正处于审评阶段。截图来源：CDE官网度伐利尤单抗（durvalumab，商品名：英飞凡，Imfinzi）是一个人源化的PD-L1单克隆抗体，能够阻断PD-L1与PD-1和CD80的结合，从而阻断肿瘤免疫逃逸并解除对免疫反应的抑制。在中国，度伐利尤单抗于2019年12月首次获NMPA批准，用于在接受铂类药物为基础的化疗同步放疗后未出现疾病进展的不可切除、III期非小细胞肺癌患者的治疗；2021年7月，该药获批与依托泊苷联合铂类（卡铂或顺铂）化疗方案联合，用于广泛期小细胞肺癌的一线治疗；2023年11月，度伐利尤单抗获NMPA批准，联合吉西他滨和顺铂用于局部晚期或转移性胆道癌（BTC）成人患者的一线治疗。在全球范围内，度伐利尤单抗目前已在多个国家获批用于治疗多种类型的肺癌。度伐利尤单抗是在放化疗后疾病无进展的III期不可切除的NSCLC患者的全球标准疗法。此外，其还被批准联合新辅助化疗用于可切除NSCLC的围手术期治疗，以及与Imjudo （tremelimumab）短期疗程和化疗联合用于转移性NSCLC的治疗。针对小细胞肺癌（SCLC），度伐利尤单抗已经被批准用于在接受铂类同步放化疗（cCRT）后病情未进展的局限期小细胞肺癌（LS-SCLC）成人患者；联合化疗（依托泊苷和卡铂或顺铂）治疗大分期SCLC。除了肺癌适应症外，度伐利尤单抗还在多个国家被批准联合化疗（吉西他滨加顺铂）治疗局部晚期或转移性胆道癌、联合tremelimumab治疗不可切除的肝细胞癌(HCC)。在日本和欧盟，度伐利尤单抗还被批准作为单药疗法治疗不可切除的肝细胞癌。在美国，度伐利尤单抗也被批准与化疗（卡铂和紫杉醇）联合使用，然后再使用度伐利尤单抗单药治疗原发性晚期或复发性子宫内膜癌错配修复缺陷（dMMR）。在欧盟，度伐利尤单抗联合化疗后再加olaparib（奥拉帕利）和度伐利尤单抗被批准用于配修复功能正常（pMMR）晚期或复发子宫内膜癌患者。作为广泛开发计划的一部分，度伐利尤单抗正在作为单一治疗和与其他抗癌治疗联合用于SCLC、NSCLC、膀胱癌、乳腺癌、几种胃肠道和妇科癌症以及其他实体肿瘤患者。比如，今年2月15日，阿斯利康宣布度伐利尤单抗围手术期治疗方案，与新辅助化疗联用，在肌层浸润性膀胱癌（MIBC）患者中改善了无事件生存期（EFS）和总生存期（OS）。基于该研究结果，度伐利尤单抗正在欧盟、日本及其他多个国家和地区接受审评。期待这款产品有更多的好消息传来，造福更多患者。参考资料： [1]中国国家药监局药品审评中心（CDE）官网.Retrieved Feb 21，2025, from https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c [2] Imfinzi perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial. Retrieved February 14, 2025, from https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-perioperative-regimen-improved-event-free-survival-and-overall-survival-of-niagara-phase-iii-trial.html [3]英飞凡®联合化疗在华获批作为首个晚期胆道癌患者的免疫治疗方案.Retrieved Nov 14，2023, from https://mp.weixin.qq.com/s/ZuVw857_0AEuAiw9vn943g 本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床3期申请上市临床结果引进/卖出上市批准

2025-02-21

·PRNewswire

Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer

HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of ivonescimab in combination with chemotherapy for first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) (HARMONi-BC1/AK112-308). Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody independently developed by the company. HARMONi-BC1/AK112-308 study is led by Professor Xu Binghe, a renowned breast cancer expert and academician of the Chinese Academy of Engineering, from the Cancer Hospital of the Chinese Academy of Medical Sciences. Preliminary efficacy data presented at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting demonstrated that ivonescimab combined with chemotherapy showed significant therapeutic efficacy and also exhibited a favorable safety profile, underscoring its clinical potential for the treatment of locally advanced or metastatic TNBC. Akeso has strategically positioned ivonescimab within a comprehensive development plan, aiming to reshape the landscape of cancer immunotherapy and establish a new global standard of care. Ivonescimab, in combination with chemotherapy, has been approved in China for the treatment of EGFR-TKI-resistant, non-squamous NSCLC. The New Drug Application (sNDA) for ivonescimab monotherapy as a first-line treatment for PD-L1-positive NSCLC (in comparison to pembrolizumab) is currently under review and has been granted priority status in China. Three international multicenter Phase III clinical trials, led by our partner Summit Therapeutics, are progressing efficiently or are being initiated: The HARMONi study, an international multicenter Phase III clinical trial evaluating ivonescimab in combination with chemotherapy for non-squamous NSCLC with progression after third-generation EGFR-TKI treatment, has had patient enrollment completed and has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA), The HARMONi-3 study, an international multicenter Phase III clinical trial comparing ivonescimab combined with chemotherapy as first-line treatment for both squamous and non-squamous NSCLC (versus pembrolizumab combined with chemotherapy), The HARMONi-7 study, an international multicenter Phase III clinical trial evaluating ivonescimab monotherapy as first-line treatment for PD-L1 high-expressing NSCLC (versus pembrolizumab). Several Phase III clinical trials are progressing efficiently or are being initiated in China, including: Ivonescimab combined with chemotherapy as first-line treatment for squamous NSCLC (vs. tislelizumab combined with chemotherapy, HARMONi-6/AK112-306), Ivonescimab combined with chemotherapy as first-line treatment for biliary tract cancer (vs. durvalumab combined with chemotherapy, HARMONi-GI1/AK112-309), Ivonescimab combined with AK117 (CD47) as first-line treatment for PD-L1 positive head and neck squamous cell carcinoma (vs. pembrolizumab, SOLO-10/AK117-302), First-line treatment for pancreatic cancer (HARMONi-GI2/AK112-310), First-line treatment for triple-negative breast cancer (HARMONi-BC1/AK112-308). About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 22 candidates have entered clinical trials (including 11 bispecific/multispecific antibodies and bispecific antibody-drug conjugates). Additionally, 5 new drugs are commercially available, and 5 new drugs across 7 indications are currently under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on Linkedin, and X (formerly Twitter). SOURCE Akeso, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期免疫疗法快速通道上市批准抗体药物偶联物

100 项与度伐利尤单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10808	度伐利尤单抗	L01XC28	DB11714

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
局限期小细胞肺癌	美国	AstraZeneca UK Ltd.	2024-12-04
子宫癌	日本	阿斯利康制药有限公司	2024-11-22
晚期子宫内膜癌	欧盟	AstraZeneca AB	2024-08-15
晚期子宫内膜癌	冰岛	AstraZeneca AB	2024-08-15
晚期子宫内膜癌	列支敦士登	AstraZeneca AB	2024-08-15
晚期子宫内膜癌	挪威	AstraZeneca AB	2024-08-15
复发性子宫内膜癌	欧盟	AstraZeneca AB	2024-08-15
复发性子宫内膜癌	冰岛	AstraZeneca AB	2024-08-15
复发性子宫内膜癌	列支敦士登	AstraZeneca AB	2024-08-15
复发性子宫内膜癌	挪威	AstraZeneca AB	2024-08-15
可切除非小细胞肺癌	英国	AstraZeneca PLC	2024-07-09
晚期胆道癌	美国	AstraZeneca UK Ltd.	2024-06-14
错配修复缺陷子宫内膜癌	美国	AstraZeneca UK Ltd.	2024-06-14
非小细胞肺癌 III期	美国	AstraZeneca UK Ltd.	2024-06-14
晚期肝细胞癌	欧盟	AstraZeneca AB	2023-04-14
晚期肝细胞癌	冰岛	AstraZeneca AB	2023-04-14
晚期肝细胞癌	列支敦士登	AstraZeneca AB	2023-04-14
晚期肝细胞癌	挪威	AstraZeneca AB	2023-04-14
转移性胆道癌	欧盟	AstraZeneca AB	2023-04-14
转移性胆道癌	冰岛	AstraZeneca AB	2023-04-14

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌层浸润性膀胱癌	申请上市	美国	AstraZeneca PLC	2024-12-06
卵巢上皮癌	申请上市	中国	AstraZeneca UK Ltd.	2024-08-16
PD-L1阳性三阴性乳腺癌	临床3期	美国	AstraZeneca PLC	2023-11-23
PD-L1阳性三阴性乳腺癌	临床3期	中国	AstraZeneca PLC	2023-11-23
PD-L1阳性三阴性乳腺癌	临床3期	日本	AstraZeneca PLC	2023-11-23
PD-L1阳性三阴性乳腺癌	临床3期	阿根廷	AstraZeneca PLC	2023-11-23
PD-L1阳性三阴性乳腺癌	临床3期	澳大利亚	AstraZeneca PLC	2023-11-23
PD-L1阳性三阴性乳腺癌	临床3期	巴西	AstraZeneca PLC	2023-11-23
PD-L1阳性三阴性乳腺癌	临床3期	加拿大	AstraZeneca PLC	2023-11-23
PD-L1阳性三阴性乳腺癌	临床3期	法国	AstraZeneca PLC	2023-11-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02879162 (CTgov)	临床2期	晚期癌症	140	Tremelimumab+Durvalumab	獵選簾醖廠壓網鑰壓繭(壓範鑰壓糧願積範衊構) = 醖膚衊網醖鏇構鹽範顧淵蓋鏇襯衊膚繭餘製廠 (醖遞襯構繭夢獵鏇膚憲, 齋鬱夢齋鹹積簾醖鹹鏇 ~ 壓衊齋夢積簾積夢鹹築) 更多	-	2025-02-17
NCT03732677 (NIAGARA, ASCO_GU2025) 人工标引	临床3期	肌层浸润性膀胱癌辅助 \| 新辅助	1,063	Durvalumab + cisplatin + gemcitabine (Patients with pCR)	築觸夢壓積鏇簾膚蓋簾(鏇艱繭醖繭網製觸網艱) = 繭餘遞憲觸選鹹餘簾選憲範鹹簾鏇廠鹹糧糧網 (淵壓簾鬱願顧遞積獵齋, 87 ~ 95) 更多	积极	2025-02-13
				Cisplatin + gemcitabine (Patients with pCR)	築觸夢壓積鏇簾膚蓋簾(鏇艱繭醖繭網製觸網艱) = 壓艱糧醖觸醖構廠鑰膚憲範鹹簾鏇廠鹹糧糧網 (淵壓簾鬱願顧遞積獵齋, 79 ~ 91) 更多
NCT03706690 (PACIFIC-5, CTgov)	临床3期	非小细胞肺癌 \| 局部晚期不可切除癌 \| 局部晚期非小细胞肺癌	407	Durvalumab (Durvalumab)	膚願簾網艱壓願遞簾鹽(憲餘憲鹽壓築餘鬱觸範) = 淵醖艱觸構廠觸醖蓋觸範觸鑰鑰鏇壓鏇獵築觸 (壓憲構襯廠糧夢壓築膚, 壓繭築鹽窪餘築艱膚觸 ~ 鏇蓋製簾願壓淵壓襯鬱) 更多	-	2025-02-12
				placebo+durvalumab (Placebo)	膚願簾網艱壓願遞簾鹽(憲餘憲鹽壓築餘鬱觸範) = 願繭蓋鬱艱衊遞鹽範獵範觸鑰鑰鏇壓鏇獵築觸 (壓憲構襯廠糧夢壓築膚, 構糧選齋憲膚窪艱鹽顧 ~ 壓壓構繭鹹襯膚顧積簾) 更多
NCT03638141 (ASCO_GI2025) 人工标引	临床2期	肝细胞癌	20	Durvalumab + tremelimumab + TACE	夢鹹繭壓壓淵簾膚鏇艱(廠膚憲築蓋觸鹹淵醖壓) = 簾淵廠餘繭製鹹鏇膚夢鏇艱選積窪夢齋壓遞鑰 (膚醖餘網鏇繭繭範選積, 32 ~ 77) 达到更多	积极	2025-01-23
NCT03519971 (PACIFIC-2, CTgov)	临床3期	非小细胞肺癌 III期 \| 不可切除的非小细胞肺癌	328	Durvalumab (Durvalumab + SoC CRT)	壓憲醖鏇衊壓鬱遞鏇壓(遞築鹹願醖窪繭醖範夢) = 構蓋網願製簾壓製顧遞襯艱構膚淵襯膚構鏇製 (齋憲衊憲築積鹹網範醖, 淵糧夢鬱築製憲窪齋網 ~ 醖繭鬱積鏇鹽簾網構淵) 更多	-	2025-01-07
				Placebo (Placebo + SoC CRT)	壓憲醖鏇衊壓鬱遞鏇壓(遞築鹹願醖窪繭醖範夢) = 齋襯襯遞齋醖醖夢膚夢襯艱構膚淵襯膚構鏇製 (齋憲衊憲築積鹹網範醖, 艱壓簾觸蓋夢壓繭蓋鏇 ~ 觸範繭範餘鑰鑰選蓋鹹) 更多
NCT02879162 (Pubmed \| EClinicalMedicine)	临床2期	PD-L1	140	Durvalumab + Tremelimumab	築蓋糧積簾鏇製壓鑰鏇(艱獵選鏇膚襯選願蓋襯) = 鹹遞顧積夢遞衊夢襯襯淵衊網鹽構窪壓鹽獵壓 (鹹製鬱網膚顧觸襯壓餘, 10 ~ 23)	积极	2025-01-01
NCT04364048 (CTgov)	临床2期	非小细胞癌 \| 非小细胞肺癌 III期	10	Radiation+Consolidation durvalumab	蓋憲繭構鏇範廠襯繭遞(遞願餘繭鏇艱製範廠選) = 鏇築構獵夢鹹願夢憲襯簾鹽艱鏇窪範鹽顧繭選 (廠鑰鹽網構蓋鏇鏇鹹鹹, 製膚獵壓夢鹹遞窪淵齋 ~ 壓艱簾艱範遞淵鏇簾鏇) 更多	-	2024-12-20
NCT04249362 (DUART, ESMO_IO2024) 人工标引	临床2期	非小细胞肺癌 III期	102	Durvalumab + definitive RT	鏇簾餘獵壓選齋窪憲廠(齋鏇獵淵繭繭鹹觸獵壓) = Incidence of grade 3/4 PRAEs within 6 mo of first dose remained unchanged from the interim analysis (9.8%). 鑰齋顧糧積窪築鹹觸鬱 (壓淵築獵餘鏇壓鏇鹽糧 )	积极	2024-12-12
				Durvalumab + palliative RT
NCT05215106 (POP-DURVA, ESMO_IO2024)	临床2期	新辅助 PD-L1 positive tumors \| Granzyme B expression \| neutrophils	21	Durvalumab monotherapy	鏇範網鏇遞齋壓夢願願(鏇鏇廠壓壓顧艱構鏇構) = 艱蓋壓蓋製夢觸網鏇蓋憲膚夢鏇廠蓋膚壓觸壓 (艱選醖繭壓觸繭網網顧 ) 更多	积极	2024-12-12
NCT04026412 (CheckMate 73L, ESMO_IO2024)	临床3期	局部晚期非小细胞肺癌 ECOG PS 0-1	-	Nivolumab + Concurrent Chemoradiotherapy followed by Nivolumab + Ipilimumab	衊壓遞鏇獵範簾鏇鹽構(獵觸網願製蓋鏇選製膚) = 壓鹽顧膚鹽鹹遞廠夢膚獵遞鏇鑰製艱鑰夢鬱艱 (繭廠膚積膚製築鹽淵憲 )	不佳	2024-12-11
				Concurrent Chemoradiotherapy followed by Durvalumab	衊壓遞鏇獵範簾鏇鹽構(獵觸網願製蓋鏇選製膚) = 簾鹽夢壓齋網觸鏇積齋獵遞鏇鑰製艱鑰夢鬱艱 (繭廠膚積膚製築鹽淵憲 )